TY - JOUR
T1 - European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update
AU - Gontero, Paolo
AU - Birtle, Alison
AU - Capoun, Otakar
AU - Compérat, Eva
AU - Dominguez-Escrig, José L.
AU - Liedberg, Fredrik
AU - Mariappan, Paramananthan
AU - Masson-Lecomte, Alexandra
AU - Mostafid, Hugh A.
AU - Pradere, Benjamin
AU - Rai, Bhavan P.
AU - van Rhijn, Bas W.G.
AU - Seisen, Thomas
AU - Shariat, Shahrokh F.
AU - Soria, Francesco
AU - Soukup, Viktor
AU - Wood, Robert
AU - Xylinas, Evanguelos N.
PY - 2024
Y1 - 2024
N2 - Background and objective: This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation. Methods: For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. Key findings and limitations: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients’ risk stratification and treating them appropriately. Conclusions and clinical implications: This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.
AB - Background and objective: This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation. Methods: For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. Key findings and limitations: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients’ risk stratification and treating them appropriately. Conclusions and clinical implications: This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.
KW - Bacillus Calmette-Guérin
KW - Bacillus Calmette-Guérin unresponsive
KW - Bladder cancer
KW - Classification
KW - Cystoscopy
KW - Diagnosis
KW - Follow-up
KW - Guidelines
KW - Intravesical chemotherapy
KW - Prognosis
KW - Radical cystectomy
KW - Transurethral resection
KW - Urothelial carcinoma
U2 - 10.1016/j.eururo.2024.07.027
DO - 10.1016/j.eururo.2024.07.027
M3 - Review article
C2 - 39155194
AN - SCOPUS:85201500018
SN - 0302-2838
VL - 86
SP - 531
EP - 549
JO - European Urology
JF - European Urology
IS - 6
ER -